drugset / Trial / NCT06737913
HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma
Phase 2
Recruiting
76 enrolled
Sun Yat-sen University
Cancer Hospital of Guangxi Medical University · collabFirst Affiliated Hospital of Fujian Medical University · collabGansu Provincial Cancer Hospital · collabHenan Provincial People's Hospital · collabHunan Provincial Cancer Hospital · collabJinshazhou Hospital of Guangzhou University of Chinese Medicine · collabShanghai Zhongshan Hospital · collabThe Seventh Affiliated Hospital of Sun Yat-sen University · collabWest China Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of Adabrelimab (arterial or intravenous administration) combined with hepatic artery FOLFOX infusion chemotherapy and Bevacizumab as the first-line treatment of advanced stage hepatocellular carcinoma. Patients will be randomized 1:1 etither to receive hepatic arterial infusion(HAI) Adabrelimab group or IV Adabrelimab group, and both groups will receive HAI FOLFOX chemotherapy and IV Bevacizumab.
Timeline
- Start
- 2025-01-03
- Primary completion
- 2028-06-30
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 1200 mg | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |